333
Participants
Start Date
November 29, 2018
Primary Completion Date
December 31, 2021
Study Completion Date
December 31, 2021
Oral Antipsychotics (OAP)
This is an observational study. Participants enrolled in this study will continue to receive routine treatment of OAPs for example, risperidone (1 to 6 mg OD to BID), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to TID) etc, as directed by their treating physician.
Mahendru Psychiatric Centre, Kanpur
Deva Institute of Health Care and Research Pvt Ltd, Varanasi
Panchshil Hospital, Ahmedabad
Ratandeep Multispeciality Hospital, Ahmedabad
GMERS Medical College and Hospital, Vadodara
Meera Hospital, Mumbai
Meditrina Institute of Medical Sciences, Nagpur
Asha hospital, Hyderabad
Kasturba Medical College Hospital, Manipal
Ahana Hospitals, Madurai
Janssen Research & Development, LLC
INDUSTRY